REGN REGENERON PHARMACEUTICALS revenue, earnings and financials

For the quarter ended June 30, 2026, REGENERON PHARMACEUTICALS reported revenue of $4.29B (up 16.7% from a year earlier), net income of $1.30B and diluted EPS of $12.23; over the last four quarters revenue was $15.5B and net income $4.33B; for the fiscal year ended December 2025 revenue was $14.3B, up 1.0% on the year before.

REGN annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $14.3B, gross profit n/a, operating income $3.58B, net income $4.50B (margin 31.4%), EPS $41.48
• Fiscal year ended Dec 2024: revenue $14.2B, gross profit n/a, operating income $3.99B, net income $4.41B (margin 31.1%), EPS $38.34
• Fiscal year ended Dec 2023: revenue $13.1B, gross profit n/a, operating income $4.05B, net income $3.95B (margin 30.1%), EPS $34.77
• Fiscal year ended Dec 2022: revenue $12.2B, gross profit n/a, operating income $4.74B, net income $4.34B (margin 35.6%), EPS $38.22
• Fiscal year ended Dec 2021: revenue $16.1B, gross profit n/a, operating income $8.95B, net income $8.08B (margin 50.2%), EPS $71.97

REGN quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $4.29B (up 16.7% year over year), net income $1.30B, EPS $12.23
• Quarter ended Mar 31, 2026: revenue $3.61B (up 19.0% year over year), net income $727M, EPS $6.75
• Quarter ended Dec 31, 2025 (from the annual report): revenue $3.88B (up 2.5% year over year), net income $845M, EPS $7.78
• Quarter ended Sep 30, 2025: revenue $3.75B (up 0.9% year over year), net income $1.46B, EPS $13.62
• Quarter ended Jun 30, 2025: revenue $3.68B (up 3.6% year over year), net income $1.39B, EPS $12.81
• Quarter ended Mar 31, 2025: revenue $3.03B (down 3.7% year over year), net income $809M, EPS $7.27
• Quarter ended Dec 31, 2024 (from the annual report): revenue $3.79B (up 10.3% year over year), net income $918M, EPS $8.12
• Quarter ended Sep 30, 2024: revenue $3.72B (up 10.6% year over year), net income $1.34B, EPS $11.54
• Quarter ended Jun 30, 2024: revenue $3.55B (up 12.3% year over year), net income $1.43B, EPS $12.41
• Quarter ended Mar 31, 2024: revenue $3.15B (down 0.5% year over year), net income $722M, EPS $6.27
• Quarter ended Dec 31, 2023 (from the annual report): revenue $3.43B (up 0.6% year over year), net income $1.16B, EPS $10.21
• Quarter ended Sep 30, 2023: revenue $3.36B (up 14.5% year over year), net income $1.01B, EPS $8.89
• Quarter ended Jun 30, 2023: revenue $3.16B (up 10.5% year over year), net income $968M, EPS $8.50
• Quarter ended Mar 31, 2023: revenue $3.16B (up 6.6% year over year), net income $818M, EPS $7.17
• Quarter ended Dec 31, 2022 (from the annual report): revenue $3.41B (down 31.0% year over year), net income $1.20B, EPS $10.48
• Quarter ended Sep 30, 2022: revenue $2.94B (down 15.0% year over year), net income $1.32B, EPS $11.66
• Quarter ended Jun 30, 2022: revenue $2.86B (down 44.4% year over year), net income $852M, EPS $7.47
• Quarter ended Mar 31, 2022: revenue $2.97B (up 17.3% year over year), net income $974M, EPS $8.61
• Quarter ended Dec 31, 2021 (from the annual report): revenue $4.95B, net income $2.23B, EPS $19.58
• Quarter ended Sep 30, 2021: revenue $3.45B, net income $1.63B, EPS $14.33

REGN cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $4.98B, share buybacks $3.44B
• Fiscal year ended Dec 2024: operating cash flow $4.42B, share buybacks $2.60B
• Fiscal year ended Dec 2023: operating cash flow $4.59B, share buybacks $2.24B
• Fiscal year ended Dec 2022: operating cash flow $5.01B, share buybacks $2.08B
• Fiscal year ended Dec 2021: operating cash flow $7.08B, share buybacks $1.65B

REGN balance sheet

• Jun 30, 2026: cash $2.46B, total assets $41.7B, total liabilities $10.0B, shareholders' equity $31.7B, long-term debt $1.99B
• Mar 31, 2026: cash $2.96B, total assets $40.9B, total liabilities $9.45B, shareholders' equity $31.4B, long-term debt $1.99B
• Dec 31, 2025: cash $3.12B, total assets $40.6B, total liabilities $9.30B, shareholders' equity $31.3B, long-term debt $1.99B
• Sep 30, 2025: cash $2.51B, total assets $40.2B, total liabilities $9.21B, shareholders' equity $31.0B, long-term debt $1.99B
• Jun 30, 2025: cash $2.00B, total assets $38.2B, total liabilities $8.28B, shareholders' equity $29.9B, long-term debt $1.99B
• Mar 31, 2025: cash $3.09B, total assets $37.5B, total liabilities $8.16B, shareholders' equity $29.4B, long-term debt $1.98B
• Dec 31, 2024: cash $2.49B, total assets $37.8B, total liabilities $8.41B, shareholders' equity $29.4B, long-term debt $1.98B
• Sep 30, 2024: cash $2.01B, total assets $37.4B, total liabilities $8.12B, shareholders' equity $29.3B, long-term debt $1.98B

What is REGN's revenue?

REGENERON PHARMACEUTICALS reported $15.5B of revenue over its last four quarters, through June 30, 2026.

Is REGN profitable?

Yes. REGENERON PHARMACEUTICALS earned $4.33B over the last four quarters.

What is REGN's EPS?

Diluted earnings per share over the last four quarters were $40.38; $12.23 in the latest quarter.

REGN ownership and insider trades · All stocks